AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02528877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo hematopoietic stem cell transplant
Study NCT02528877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02528877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study NCT02528877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT02528877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT01788826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic mesh
Description: Closure of midline laparotomy using a prophylactic mesh. The midline is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1. Then, a prefascial large-pore low-weight 5 cm wide polypropylene mesh (Optilene Mesh Elastic, B.Braun) is fixed covering the midline closure. The mesh is fixed in the prefascial plane with absorbable monofilament interrupted sutures, USP 2/0.
Study NCT01788826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No prophylactic mesh closure
Description: Closure of midline laparotomy without mesh. The laparotomy is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1.
Study NCT03850483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: PF-06700841 topical cream
Study NCT03850483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (Placebo)
Description: Vehicle topical cream
Study NCT00581672 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires of quality of life
Description: Subjects will be asked to complete the MAX-PC along with additional psychosocial questionnaires which include anxiety, depression coping methods, resilience spirituality, religiosity, and quality of life measures and will take approximately one 30 to 45 minutes to complete by patient.
Study NCT01080482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus 5 mg Capsule
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Study NCT01080482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus 5 mg Capsule
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Study NCT02199431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167
Study NCT02199431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study NCT02309320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171
Study NCT02309320 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02153177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair
Description: Arthroscopic procedure
Study NCT02153177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole
Description: In addition to pain medication after the procedure patients will receive Ibuprofen and Omeprazole. Omeprazole is given to minimize the gastrointestinal side effects of Ibuprofen.
Study NCT02153177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/Acetaminophen
Description: Hydrocodone/Acetaminophen is given for pain control after the surgery.
Study NCT03302169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy with posterior rhabdosphincter reconstruction
Description: To suture the Denonvilliers fascia and bladder to the median dorsal raphe according to Rocco technique.
Study NCT03302169 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical prostatectomy without posterior rhabdosphincter reconstruction
Description: Standard technique with a running suture to perform the urethrovesical anastomosis
Study NCT03004781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting program
Study NCT03195829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Stimulation
Description: The intervention group performed 12-week, 90-minutes per week of cognitive stimulation in group using a tablet with a commercial software with specific exercises to train the cognitive functioning and promote the relation ties in group-session.The program's difficulty level was adjusted to the MMSE score, and was gradually increased.
Study NCT03195829 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multimedia-based internet
Description: The active control group had access to different Multimedia contents (travel, photos, music, TV program, cooking recipes) using a tablet, 90-minutes per week each week during 3-months. Each group session was centered in a particular topic, participants were able to select different media free available in Internet.
Study NCT01356823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30μg HPV
Description: Participants would intramuscularly receive 30μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
Study NCT01356823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60μg HPV
Description: Participants would intramuscularly receive 60μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
Study NCT02312739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-office Transcervical Sterilization (Essure®)
Description: The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.
Study NCT02312739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-office Transcervical Sterilization (Essure®)
Description: The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.
Study NCT02312739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oral pain medications
Description: one 5/325mg hydrocodone/acetaminophen (Vicodin) tablet and one 1mg Lorazepam tablet given to patients randomized to the active comparator arm at least 30 minutes before the procedure
Study NCT02312739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular Ketorolac
Description: 30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure
Study NCT02312739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Ketorolac
Description: 30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure
Study NCT02312739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pills
Description: Two placebo bills given to patients randomized to the experimental arm at least 30 minutes prior to the procedure
Study NCT02312739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen at 5L/min given to patients randomized to the active comparator arm
Study NCT02312739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous oxide with a maximum titration of up to 70% given to patients randomized to the experimental arm
Study NCT03555890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine ODT 5 mg
Description: Levocetirizine ODT will be available as oral disintegrating tablet. Subjects will receive a single dose of 5 mg levocetirizine ODT. In Part 1, subjects will receive levocetirizine ODT with 150 mL water and in Part 2 subjects will receive levocetirizine ODT without water.
Study NCT05436691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information and Coping with Anxiety Training
Description: Informing and Coping with Anxiety Training was given to the experimental group before the operation through a prepared booklet.The information booklet about the training was created by the researchers by reviewing the current literature. The booklet provides information for patients scheduled for hysterectomy about how to cope with surgery-related anxiety. The booklet provides information on what the hysterectomy is, why it is performed, what risks it has, what should be done before, during and after the hysterectomy, what rules the patient should comply with after hysterectomy, in which cases she should present to the health institution, what changes she might experience in her social, physical, sexual and emotional life after the surgery. The booklet also provides information about discharge training and coping with anxiety.
Study NCT01356823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90μg HPV
Description: Participants would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
Study NCT01356823 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Participants would intramuscularly receive 10μg of hepatitis B vaccine at 0, 1, 6 month for 3 doses.
Study NCT01697748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silver-impregnated dressing
Description: Silver-impregnated dressing placed over Cesarean wound after skin closure; the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
Study NCT01697748 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Telfa pad dressing
Description: Telfa pad dressing placed over Cesarean wound after skin closure; the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
Study NCT03894826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat 100 MG
Description: Vorinostat administered by mouth, once daily at a dose of 230 mg/m2/day for a total of 6 weeks
Study NCT00093912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine
Study NCT00093912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium nitroprusside
Study NCT03468660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory training with feedback
Description: Experimental group receives phoneme-level and sentence-level training with feedback
Study NCT03468660 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Listening paradigm with no feedback
Description: Active controls listen to acoustic stimuli with no feedback
Study NCT00448266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensified Cyclophophamide, Carboplatin and Thiotepa
Description: 2 courses of Intensified Cyclophophamide, Carboplatin and Thiotepa with PBPC support
Study NCT03456869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Specific Implant
Description: The patient specific implant is used to simultaneously complete the reposition and fixation of the chin.
Study NCT03615079 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy
Description: An 8-week, internet-based cognitive behavioral therapy (CBT) program for depression
Study NCT04190238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Super inductive system (high frequency electromagnetic field)
Description: Super inductive system (high frequency electromagnetic field)
Study NCT01889537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The patient will receive virtual reality during a burn care procedure
Study NCT00448266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dose dense adriamycine and cyclophosphamide
Description: dose dense adriamycine and cyclophosphamide, Q 2 weeks
Study NCT04190238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Super inductive system (high frequency electromagnetic field)
Description: Super inductive system (high frequency electromagnetic field)
Study NCT04190238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: specific for spasticity
Study NCT00513695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO
Study NCT00513695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00513695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00513695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO
Study NCT00513695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT00513695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00513695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00513695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT03827499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB dietary supplementation
Description: Intervention groups including HMB supplementation (Ex-HMB and NoEx-HMB) will receive a 3 g daily dose of free acid HMB in powder form dissolved freely into 250 mL of water during a 24-week intervention
Study NCT02385448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest
Description: The dienogest group will receive dienogest 2mg daily for 24 months postoperatively
Study NCT04190238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: specific for spasticity
Study NCT02385448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microgynon
Description: The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
Study NCT01753024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Enteral nutrition (EN)
Description: All patients enrolled in this study must carry out nutritional support by enteral nutrition
Study NCT05935501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formaderm Young
Description: Dermal filler injection to facial areas.
Study NCT05935501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Dermal filler injection to facial areas.
Study NCT03722160 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Solo TympanostomyTube Device
Description: The Solo Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
Study NCT03360461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMI-137
Description: EMI-137 - a fluorescent c-Met receptor targeted peptide
Study NCT02553330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Study NCT02553330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ruxolitinib Phosphate Cream
Study NCT02553330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate Cream
Study NCT02945865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain assessment
Description: Pain assessment with assessment tools
Study NCT03403725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN1309
Description: MEN1309 solution for intravenous infusion once every 3 weeks
Study NCT04100447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: A total of 700 mL of study drug should be completely consumed orally 2-12 hours prior to surgery as a split dose; 350 mL 6-12 hours prior to surgery and the remaining 350 mL 2-6 hours prior to surgery.
Study NCT00373334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nizatidine (axid)
Description: nizatidine (axid)
Study NCT01114542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
Study NCT01114542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
Study NCT00373334 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01659021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 150 mg tablets administered orally twice daily
Study NCT01659021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Administered intravenously
Study NCT01659021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab
Description: Administered intravenously
Study NCT01812837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
Study NCT01812837 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Aminolevulinic Acid
Description: Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
Study NCT01812837 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Blue light
Description: Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)
Study NCT05319340 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: prescribing anticoagulant therapy
Description: Patients who need anticoagulants were consulted by a cardiologist with subsequent recommendations
Study NCT03571854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group PCV-VG
Description: Pressure controlled ventilation-volume guaranteed
Study NCT03571854 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group VCV
Description: Volume controlled ventilation
Study NCT01928654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micropulse laser treatment
Description: Device for subthreshold treatment of the retina, by decomposing a continuos wave of laser in micropulses, with 5% duty cycle, 200 milliseconds, 100 microns, and power adjusted according to patient's diopter transparency and pigmentation.
Study NCT01928654 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser modified ETDRS
Description: Device for visible treatment of the retina, with direct treatment of microaneurysms or grid pattern covering the area of retinal edema.
Study NCT03793075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine 5 mcg/kg/min will be used as intravenous anesthetic infusion
Study NCT03793075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: propofol 17 mcg /kg/min
Study NCT03210233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood test, skin testing and challenge testing.
Description: Skin Prick Testing (SPT) and Intradermal Testing (IDT). We will follow the STARD framework for reporting studies of diagnostic accuracy
Study NCT01974570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marealis refined peptide concentrate
Description: 2 tablets, once per day before noon
Study NCT01974570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets, once per day before noon
Study NCT03698318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tested product n°1
Description: 1 capsule (26% of gingerol/shogaol in 100 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
Study NCT03698318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tested product n°2
Description: 1 capsule (38.6% of gingerol/shogaol in 74.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)